New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ILMN;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 16, 2014
08:47 EDTRHHBYHemispherx Ampligen provides anti-tumor activity
Subscribe for More Information
05:46 EDTRHHBYRoche launches PCR molecular diagnostic system for point of care environment
Subscribe for More Information
December 15, 2014
05:24 EDTRHHBYExelixis announces Genentech files NDA for cobimetinib, vemurafenib combination
Exelixis (EXEL) announced its collaborator Genentech, a member of the Roche Group (RHHBY), has completed the filing of its New Drug Application, or NDA, with the FDA for cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib for previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Cobimetinib has received Fast Track designation by the FDA. Roche submitted a Marketing Authorization Application for the combination to the European Medicines Agency in September of this year. The NDA is based on data from the coBRIM trial, a phase 3 pivotal trial conducted by Genentech in 495 patients with BRAF V600 mutation-positive unresectable locally advanced or metastatic melanoma.
December 12, 2014
05:52 EDTRHHBYRoche announces retirement of Genentech research head
Subscribe for More Information
December 9, 2014
12:22 EDTRHHBYPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
07:44 EDTRHHBYAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
December 5, 2014
11:33 EDTRHHBYGenentech to present clinical data at ASH
Subscribe for More Information
December 3, 2014
16:30 EDTILMNOn The Fly: Closing Wrap
Stocks on Wall Street opened quietly and trading remained muted through another session. Despite a host of economic data, including the Fedís Beige book report, the market moved in a narrow range, albeit toward record levels. The Fedís report confirmed the economy continues to improve, but at a slow pace. ECONOMIC EVENTS: In the U.S., Automatic Data Processing reported private payrolls increased 208k in November, versus expectations for 222K. Q3 nonfarm productivity grew 2.3%, versus expectations for an increase of 2.4%. Markit's final services PMI for November dropped to 56.2, which was below the 56.3 November flash print and down from October's 57.1 reading. The Institute for Supply Management's composite non-manufacturing index jumped to 59.3 in November from 57.1 in October, beating expectations for it to remain unchanged. The Federal Reserve Beige Book stated that the country's economy continued to expand in October and November. Consumer spending rose in most areas and the employment situation improved in many areas, while demand for nonfinancial services rebounded and lending held steady or increased, districts reported to the central bank. COMPANY NEWS: Carbonite (CARB) jumped $2.68, or 22.79%, to $14.44 after J2 Global (JCOM) offered to acquire all of the company's outstanding shares for $15.00 per share in cash. Carbonite's board will carefully "review and consider the offer," the company announced following its receipt of the unsolicited takeover bid. Investors reacted favorably to J2 Global's offer, sending its shares up $3.36, or 5.9%, to $60.33 as well. MAJOR MOVERS: Among the notable gainers was Sequenom (SQNM), which rose 72c, or 23.61%, to $3.77 after the company and a unit of Illumina (ILMN) agreed to settle all their pending infringement claims. Also higher was UTi Worldwide (UTIW), which jumped $2.34, or 20.28%, to $13.88 after Bloomberg, citing people with knowledge of the matter, reported that the company could reach an agreement to sell itself to Denmark-based DSV A/S as soon as this month. Among the noteworthy losers was Puma Biotechnology (PBYI), which sunk $27.33, or 12.15%, to $197.67 after the company delayed the filing for neratinib from the first half of 2015 to Q1 of 2016. Also lower were Class B shares of Brown-Forman (BF.B), which fell $3.75, or 3.91%, to $92.25 after the maker of Jack Danielís and other spirits reported lower than expected earnings and lowered its FY15 EPS view. INDEXES: The Dow rose 33.07, or 0.18%, to 17,912.62, the Nasdaq gained 18.66, or 0.39%, to 4,774.47, and the S&P 500 added 7.78, or 0.38%, to 2,074.33.
12:39 EDTILMNOn The Fly: Midday Wrap
Subscribe for More Information
10:47 EDTILMNSequenom settlement positive but reflected in stock price, says Ladenburg
Ladenburg views the settlement reached between Sequenom (SQNM) and Illumina (ILMN) as a near-term positive for Sequenom that gives more clarity on the competitive landscape, lowers its legal expenses and brings in needed capital. However, the firm believes the near-term financial benefit is reflected in the stock's valuation and maintains its Neutral rating on Sequenom shares.
09:23 EDTILMNOn The Fly: Pre-market Movers
Subscribe for More Information
06:07 EDTILMNIllumina and Sequenom end patent dispute with partnership in prenatal testing
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use